The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells

The combination of gemcitabine (Gem), busulfan (Bu) and melphalan (Mel) is a promising regimen for autologous stem-cell transplantation (SCT) for lymphomas. To further improve the efficacy of [Gem+Bu+Mel], we added PARP inhibitor olaparib (Ola). We hypothesized that Ola would inhibit the repair of d...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Leuk Lymphoma
Huvudupphovsmän: Valdez, Benigno C., Li, Yang, Murray, David, Liu, Yan, Nieto, Yago, Champlin, Richard E., Andersson, Borje S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5526721/
https://ncbi.nlm.nih.gov/pubmed/28394191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1306647
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk